Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

Journal article

The UKMRA RADAR study is a phase II/III clinical trial for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. It offers a risk‐adapted approach with the addition of isatuximab for genetically high‐risk patients, evaluated using local cytogenetics laboratories rather than centralised testing. We have observed excellent overall success rates, with > 90% patients assigned to a risk‐adapted pathway following cytogenetic testing in 25 local laboratories nationwide, with clinically‐relevant turnaround times allowing > 70% patients to commence isatuximab at the earliest opportunity if indicated. This paves the way for providing standard‐of‐care risk‐adapted treatment for multiple myeloma patients in the UK.

Authors: Mehta, D; Cicero, R; Chiecchio, L; Asher, S; Kaiser, M

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Wiley
• Journal: eJHaem
• Publication date: 2025-06-09
• Acceptance date: 2024-09-04
• DOI: 10.1002/jha2.1015
• EISSN: 2688-6146
• ISSN: 2688-6146
• Language: English
• Keywords: risk stratification; cytogenetics; multiple myeloma